Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27 Kip1 phosphorylation on Thr187 and accumulates p27 Kip1 in the nucleus: Implications for breast cancer therapy

Molecular and Cellular Biology

Volumn 29, Issue 8, 2009, Pages 2254-2263

  Kazi, Aslamuzzaman ^a,b   Carie, Adam ^a   Blaskovich, Michelle A ^a   Bucher, Cynthia ^a   Thai, Van ^a   Moulder, Stacy ^a,b   Peng, Hairuo ^c   Carrico, Dora ^c   Pusateri, Erin ^c   Warren J Pledger, ^a,b   Berndt, Norbert ^a   Hamilton, Andrew ^c   Sebti, Saïd M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GERANYLGERANYLTRANSFERASE 1; GERANYLTRANSFERASE; GGTI 2417; GGTI 2418; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MICE; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN PRENYLATION; THREONINE;

MURINAE; MUS MUSCULUS;

EID: 64649106561     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01029-08     Document Type: Article

References (54)

1. Adnane, J., F. A. Bizouarn, Y. Qian, A. D. Hamilton, and S. M. Sebti. 1998. p21(WAFl/CIPl) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor (3- and Sp1-responsive element: involvement of the small GTPase RhoA. Mol. Cell. Biol. 18:6962-6970.
2. Alkarain, A., R. Jordan, and J. Slingerland. 2004. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J. Mammary Gland Biol. Neoplasia 9:67-80.
3. Badache, A, and A. Gonçalves. 2006. The ErbB2 signaling network as a target for breast cancer therapy. J. Mammary Gland Biol. Neoplasia 11:13-25.
4. Bagui, T. K., R. J. Jackson, D. Agrawal, and W. J. Pledger. 2000. Analysis of cyclin D3-cdk4 complexes in fibroblasts expressing and lacking p27(kip1) and p21(cip1). Mol. Cell. Biol. 20:8748-8757.
5. Barbareschi, M. 1999. p27 expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv. Clin. Pathol. 3:119-127.
6. Kip1 that causes stem cell eexpansion and a multiple tumor phenotype. Genes Dev. 21:1731-1746.
7. Blain, S. W., H. I. Scher, C. Cordon-Cardo, and A Koff. 2003. p27 as a target for cancer therapeutics. Cancer Cell 3:111-115.
8. Kip1 metabolism: a fascinating labyrinth. Cell Cycle 6:1053-1061.
9. Burbelo, P., A. Wellstein, and R. G. Pestell. 2004. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res. Treat. 84: 43-48.
10. Cariou, S., C. Catzavelos, and J. M. Slingerland. 1998. Prognostic implications of expression of the cell cycle inhibitor protein p27Kipl. Breast Cancer Res. Treat. 52:29-41.
11. Catzavelos, C., N. Bhattacharya, Y. C. Ung, J. A, Wilson, L. Roncari, C. Sandhu, P. Shaw, H. Yeger, I. Morava-Protzner, L. Kapusta, E. Franssen, K. I. Pritchard, and J. M. Slingerland. 1997. Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer. Nat. Med. 3:227-230.
12. Chu, I., J. Sun, A. Arnaout, H. Kahn, W. Hanna, S. Narod, P. Sun, C.-K. Tan, L. Hengst, and J. M. Slingerland. 2007. p27 phosphorylation by Src regulates inhibition of cyclin E-cdk2. Cell 128:281-294.
13. Chu, I. M., L. Hengst, and J. M. Slingerland. 2008. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8:253-267.
14. Coleman, M. L., R. M. Densham, D. R. Croft, and M. F. Olson. 2006. Stability of p21Wafl/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene 25:2708-2716.
15. 1phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 5:355-366.
16. Croft, D. R., and M. F. Olson. 2006. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol. Cell. Biol. 26:4612-4627.
17. Dan, H. C., K. Jiang, D. Coppola, A, Hamilton, S. V. Nicosia, S. M. Sebti, and J. Q. Cheng. 2004. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23:706-715.
18. Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res. 67:9238-9243.
19. Drexler, H. C. 2003. The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2:438-441.
20. Falsetti, S. C., D.-A. Wang, H. Peng, D. Carrico, A. D. Cox, C. J. Der, A. D. Hamilton, and S. M. Sebti. 2007. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis, and RalA to inhibit anchorage-independent growth. Mol. Cell. Biol. 27: 8003-8014.
21. Fritz, G., and B. Kaina. 2006. Rho GTPases: promising cellular targets for novel anticancer drags. Curr. Cancer Drag Targets 6:1-14.
22. Gelb, M. H., L. Brunsveld, C. A. Hrycyna, S. Michaelis, F. Tamanoi, W. C. Van Voorhis, and H. Waldmann. 2006. Therapeutic intervention based on protein prenylation and associated modifications. Nat. Chem. Biol. 2:518-23.
23. Grimmler, M., Y. Wang, T. Mund, Z. Cilenšek, E.-M. Keidel, M. B. Waddell, H. Jäkel, M. Kullmann, R. W. Kriwacki, and L. Hengst. 2007. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128:269-280.
24. Han, S., K. Park, H. Y. Kim, M. S. Lee, H. J. Kim, and Y. D. Kim. 1999. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res. Treat. 55:161-167.
25. 1 transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 276:48937-48943.
26. 1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272:13-16.
27. Hu, W., C. J. Bellone, and J. J. Baldassare. 1999. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity. J. Biol. Chem. 274:3396-3401.
28. Ishida, N., T. Hara, T. Kamura, M. Yoshida, K. Nakayama, and K. I. Nakayama. 2002. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 277:14355-14358.
29. Ishida, N., M. Kitagawa, S. Hatakeyama, and K.-I. Nakayama. 2000. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J. Biol. Chem. 275:25146-25154.
30. 2 phase. Nat. Cell Biol. 6:1229-1235.
31. Kaufmann, S. H., S. Desnoyers, Y. Ottaviano, N. E. Davidson, and G. G. Poirier. 1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976-3985.
32. Kossatz, U., J. Vervoorts, I. Nickeleit, H. A. Sundberg, J. S. C. Arthur, M. P. Manns, and N. P. Malek. 2006. C-terminal phosphorylation controls the stability and function of p27Kip1. EMBO J. 25:5159-5170.
33. Le, X. F., F. Pruefer, and R. C. Bast, Jr. 2005. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4:87-95.
34. Lerner, E. C., Y. Qian, M. A. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A. D. Cox, C. J. Der, A. D. Hamilton, and S. M. Sebti. 1995. Ras CAAX peptido-mimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270:26802-26806.
35. Lerner, E. C., Y. Qian, A D. Hamilton, and S. M. Sebti. 1995. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyl-transferase I inhibitor. J. Biol. Chem. 270:26770-26773.
36. 1 arrest. Nat. Med. 8:1153-1160.
37. Min, Y. H., J. W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee. 2004. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res. 64:5225-5231.
38. Peng, H., D. Carrico, V. Thai, M. Blaskovich, C. Bucher, E. E. Pusateri, S. M. Sebti, and A. D. Hamilton. 2006. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyl-transferase-I. Org. Biomol. Chem. 4:1768-1784.
39. Ridley, A. J. 2004. Rho proteins and cancer. Breast Cancer Res. Treat. 84:13-19.
40. Sebti, S. M. 2005. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7:297-300.
41. Sebti, S. M., and C. J. Der. 2003. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat. Rev. Cancer. 3:945-951.
42. Sebti, S. M., and A. D. Hamilton. 2000. Farnesyltransferase and geranylgera-nyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584-6593.
43. 1-phase progression. Genes Dev. 13:1501-1512.
44. Shin, I., F. M. Yakes, F. Rojo, N. Y. Shin, A. V. Bakin, J. Baselga, and C. L. Arteaga. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8:1145-1152.
45. Sjogren, A.-K., K. M. E. Andersson, m. Liu, B. A. Cutts, C. Karlsson, A. M. Wahlstrom, M. Dalin, C. A Weinbaum, P. J. Casey, A. Tarkowski, B. Swolin, S. G. Young, and M. O. Bergo. 2007. GGTase-1 deficiency reduces tumor formation and improves survival in mice with K-Ras-induced lung cancer. J. Clin. Investig. 117:1294-1304.
46. Sun, J., M. A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, R. D. Bailey, A. D. Hamilton, and S. M. Sebti. 1999. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 59:4919-4926.
47. Sun, J., Y. Qian, Z. Chen, J. Marfurt, A. D. Hamilton, and S. M. Sebti. 1999. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphor-ylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J. Biol. Chem. 274:6930-6934.
48. Vargo-Gogola, T., and J. M. Rosen. 2007. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 7:659-672.
49. Viglietto, G., M. L. Motti, P. Bruni, R. M. Melillo, A, D'Alessio, D. Califano, F. Vinci, G. Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, and M. Santoro. 2002. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:1136-1144.
50. 1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J. Biol. Chem. 272:27224-27229.
51. Walker, K., and M. F. Olson. 2005. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 15:62-68.
52. 1 progression through the independent regulation of cyclin D1 and p27. J. Biol. Chem. 272:32966-32971.
53. Kip1 inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 66:2162-2172.
54. Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:241-269.